1500 E. Medical Center Drive, 3431 Rogel Cancer Center
Ann Arbor, MI 48109
Available to mentor
Marina A. Grachtchouk, Ph.D. is an Associate Research Scientist in the Department of Dermatology at the University of Michigan in Ann Arbor. A central member of the U-M Skin Cancer Biology Program (PI: Anj Dlugosz) based in the U-M Rogel Cancer Center, Dr. Grachtchouk is engaged in ongoing multidisciplinary research focusing on the role of the Hh pathway in skin and epithelial cell cancers and developmental biology. She serves as a frequent mentor/advisor for the Undergraduate Research Opportunities Program (UROP) and supplies research training to students, post-docs and other learners within the Dlugosz lab.
An accomplished molecular biologist, Dr. Grachtchouk specializes in the design and development of novel transgenic mouse models of skin disease. She is deeply engaged in team science and is sought out for her expertise in animal model development and her thorough knowledge of Hedgehog (Hh) signaling and hair follicle stem cell biology. Dr. Grachtchouk has established several novel mouse models to advance research examining Hh pathway, stem cell biology and cancer biology involving the stomach, skin and other organ systems. She recently oversaw the development of a mouse model of aging skin to support investigation of the role of aging skin’s extracellular matrix microenvironment on cancer tumorigenesis. As a member of the U-M Skin Biology and Diseases Resource-based Center (SBDRC), Dr. Grachtchouk provides guidance and expertise to center members and other researchers through the SBDRC Animal Modeling Core. Furthermore, she is involved in ongoing collaborations with multiple investigators both internal and external to the U-M.
Dr. Grachtchouk has contributed to landmark research studying the Hh signaling pathway, and has multiple highly cited and first authorship publications. She regularly presents her research work at annual meetings of Society for Investigative Dermatology and at International Investigative Dermatology (Tri-society) Meetings.
Dr. Grachtchouk received her PhD in Molecular Biology from the Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia in 1991. She received postdoctoral training at the University of St. Andrews, St. Andrews, Scotland (1995-1996); the Engelhardt Institute of Molecular Biology, Moscow, Russia (1996-1997); and the University of Michigan Department of Dermatology in Ann Arbor (1997-2000). Dr. Grachtchouk joined the Dermatology Department research faculty in 2008, rising to the rank of Assistant Research Scientist in 2013.
-
Research FellowUniversity of Michigan–Ann Arbor, Dermatology, 2000
-
Research FellowUniversity of St Andrews, St Andrews, 1996
-
Staff ScientistAll-Russian Scientific Research Institute of Animal Husbandry, Genetic Engineering, 1986
-
Postgraduate training in Special Higher Qualification CoursesLomonosov Moscow State University, Pushchino, 1986
-
PhDEngelhardt Institute of Molecular Biology, Laboratory of Biosynthesis of Nucleic Acids, Russian Academy of Sciences, Moscow, 1991
-
MSMoscow Veterinary-Medicine Academy, Department of Biochemistry, Moscow, 1982
Cell of origin of epithelial skin tumors
Role of Hedgehog signaling in skin and extracutaneous tumor progression and maintenance, conditional mouse models of cancer
Embryonic signaling pathways in skin appendage development
-
Meyer-Schuman R, Cale AR, Pierluissi JA, Jonatzke KE, Park YN, Lenk GM, Oprescu SN, Grachtchouk MA, Dlugosz AA, Beg AA, Meisler MH, Antonellis A. HGG Adv, 2024 Jul 18; 5 (3): 100324Journal ArticleA model organism pipeline provides insight into the clinical heterogeneity of TARS1 loss-of-function variants.
DOI:10.1016/j.xhgg.2024.100324 PMID: 38956874 -
Meyer-Schuman R, Cale AR, Pierluissi JA, Jonatzke KE, Park YN, Lenk GM, Oprescu SN, Grachtchouk MA, Dlugosz AA, Beg AA, Meisler MH, Antonellis A. 2024 Mar 27;PreprintPredictive modeling provides insight into the clinical heterogeneity associated with TARS1 loss-of-function mutations.
DOI:10.1101/2024.03.25.586600 PMID: 38585737 -
Veniaminova NA, Jia YY, Hartigan AM, Huyge TJ, Tsai S-Y, Grachtchouk M, Nakagawa S, Dlugosz AA, Atwood SX, Wong SY. Cell Rep, 2023 Sep 26; 42 (9): 113121Journal ArticleDistinct mechanisms for sebaceous gland self-renewal and regeneration provide durability in response to injury.
DOI:10.1016/j.celrep.2023.113121 PMID: 37715952 -
Pedersen EA, Grachtchouk MA, Verhaegen ME, Syu L, Harms PW, Gharaee-Kermani M, Ma F, Gudjonsson J, Ito M, Dlugosz A. Journal of Investigative Dermatology, 2023 May; 143 (5): s220Proceeding / Abstract / Poster1282 Basal cell carcinoma pigmentation is associated with melanocyte proliferation and expression of the melanocyte mitogens endothelin 1 and 2 by tumor cells
DOI:10.1016/j.jid.2023.03.1296 -
Veniaminova NA, Jia Y, Hartigan A, Huyge T, Tsai S, Grachtchouk MA, Nakagawa S, Dlugosz A, Atwood S, Wong S. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023 143 (5): S241 - S241.Proceeding / Abstract / PosterCellular and molecular characterization of sebaceous gland self-renewal and regeneration following complete genetic ablation
-
Grachtchouk M, Pedersen EA, Harms PW, Hoover A, Pyrozhenko D, Alam A, Lingam N, Dlugosz AA. Journal of Investigative Dermatology, 2022 May; 142 (8): s20 - s20.Proceeding / Abstract / PosterThe impact of aging on murine basal cell carcinoma development
DOI:10.1016/j.jid.2022.05.050 -
Verhaegen ME, Harms PW, Van Goor JJ, Arche J, Patrick MT, Wilbert D, Zabawa H, Grachtchouk M, Liu C-J, Hu K, Kelly MC, Chen P, Saunders TL, Weidinger S, Syu L-J, Runge JS, Gudjonsson JE, Wong SY, Brownell I, Cieslik M, Udager AM, Chinnaiyan AM, Tsoi LC, Dlugosz AA. J Clin Invest, 2022 Apr 1; 132 (7):Journal ArticleDirect cellular reprogramming enables development of viral T antigen-driven Merkel cell carcinoma in mice.
DOI:10.1172/JCI152069 PMID: 35143422 -
Trieu KG, Tsai S-Y, Eberl M, Ju V, Ford NC, Doane OJ, Peterson JK, Veniaminova NA, Grachtchouk M, Harms PW, Swartling FJ, Dlugosz AA, Wong SY. Cell Rep, 2022 May 3; 39 (5): 110779Journal ArticleBasal cell carcinomas acquire secondary mutations to overcome dormancy and progress from microscopic to macroscopic disease.
DOI:10.1016/j.celrep.2022.110779 PMID: 35508126